Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Protalix BioTherapeutics, Inc.v324485_ex99-1.htm




Washington, D.C.  20549





Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): September 27, 2012


Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)



Florida   001-33357   65-0643773

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)


2 Snunit Street   20100
Science Park, POB 455    
Carmiel, Israel    
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)



 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01. Other Events


On September 27, 2012, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that it has received marketing authorization from the Israeli Ministry of Health for ElelysoTM (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with Type 1 Gaucher disease. Elelyso will be marketed in Israel by Protalix Ltd., the holder of all marketing rights to Elelyso in the Israeli market.


A copy of the press release is filed as Exhibit 99.1.


Item 9.01.  Financial Statements and Exhibits




99.1Press release dated September 27, 2012






Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Date: September 27, 2012 By:         /s/ David Aviezer, Ph.D.  

Name:    David Aviezer, Ph.D.

Title:      President and Chief Executive Officer